Description: Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung. Its products also comprise GB2064, which is in Phase I/IIa for the treatment of myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase I/IIa for the treatment of fibrosis related to non-alcoholic steatohepatitis, as well as development of other related indications, including cancer. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.
Home Page: galecto.com
GLTO Technical Analysis
75 State Street
Boston,
MA
02109
United States
Phone:
457 070 5210
Officers
| Name | Title |
|---|---|
| Dr. Hans T. Schambye M.D., Ph.D. | Co-Founder, Pres, CEO & Director |
| Mr. Jonathan P. Freve CPA, CPA | Chief Financial Officer |
| Mr. Anders Pedersen | Chief Operating Officer |
| Mr. Ulf J. Nilsson | Co-Founder |
| Dr. Hakon Leffler | Co-Founder |
| Prof. Tariq Sethi M.D., B.Sc., M.A., Ph.D., FRCP | Co-Founder & Member of the Clinical Advisory Board - IPF |
| Mr. Garrett Winslow Esq. | Sr. VP, Gen. Counsel & Corp. Sec. |
| Prof. Bertil Lindmark M.D., Ph.D. | Chief Medical Officer |
| Dr. Stephanie Oestreich Ph.D. | Chief Bus. Officer |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.5276 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2020-10-29 |
| Fiscal Year End: | December |
| Full Time Employees: | 40 |